CD73low B-cell phenotypes and distinct cytokine profiles in patients with active anti-Jo-1 antibody positive idiopathic inflammatory myopathies
Authors' conclusion
Since CD73 has an immunoregulatory function by modulating the ATP/adenosine pathway, which is also targeted by methotrexate, the low CD73 B-cell expression in anti-Jo-1 antibody-positive IIM may lead to B-cell hyperactivation.
Study context
- Population
- Patients with anti-Jo-1 antibody positive idiopathic inflammatory myopathies (IIM)
- Participants
- 16 patients
- Comparison
- Active vs inactive anti-Jo-1 antibody positive IIM
- Untreated active IIMn = 7
- Active and treated IIMn = 4
- Inactive IIMn = 5reference
Methodological detailsmultiparameter spectral flow cytometry, dimensionality reduction and clustering analysis
- Multiparameter spectral flow cytometry
- Dimensionality reduction and clustering analysis
Main finding
As reported in the abstract
- Anti-Jo-1 antibody levels correlated positively to disease activity
- Significantly lower CD73 expression on naïve, switched memory and double negative B cells in active IIM
- Expansions of CD73- IgM+ naïve B cells and CD73- CD95+ switched memory B cells in active IIM
- CD73+CD21+ unswitched memory B cells decreased in active IIM
- Significantly higher serum B-cell activating factor, inducible protein-10, IL-6 and sCD40L in active IIM, correlating with changes in B-cell populations
Original publication
CD73low B-cell phenotypes and distinct cytokine profiles in patients with active anti-Jo-1 antibody positive idiopathic inflammatory myopathies. RMD Open. Published 9 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →